|
1
|
Gala K and Chandarlapaty S: Molecular
pathways: HER3 targeted therapy. Clin Cancer Res. 20:1410–1416.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tomas A, Futter CE and Eden ER: EGF
receptor trafficking: Consequences for signaling and cancer. Trends
Cell Biol. 24:26–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carlsson J, Wester K, De La Torre M,
Malmström PU and Gårdmark T: EGFR-expression in primary urinary
bladder cancer and corresponding metastases and the relation to
HER2-expression. On the possibility to target these receptors with
radionuclides. Radiol Oncol. 49:50–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Caiazza F, Elliott L, Fennelly D, Sheahan
K, Doherty GA and Ryan EJ: Targeting EGFR in metastatic colorectal
cancer beyond the limitations of KRAS status: Alternative
biomarkers and therapeutic strategies. Biomark Med. 9:363–375.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karachaliou N, Gimenez-Capitan A,
Drozdowskyj A, Viteri S, Moran T, Carcereny E, Massuti B,
Vergnenegre A, de Marinis F, Molina MA, et al: ROR1 as a novel
therapeutic target for EGFR-mutant non-small-cell lung cancer
patients with the EGFR T790M mutation. Transl Lung Cancer Res.
3:122–130. 2014.PubMed/NCBI
|
|
6
|
Yarden Y and Schlessinger J: Epidermal
growth-factor induces rapid, reversible aggregation of the purified
epidermal growth-factor receptor. Biochemistry. 26:1443–1451. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2014. View Article : Google Scholar
|
|
8
|
Carcereny E, Morán T, Capdevila L, Cros S,
Vilà L, de Los Llanos Gil M, Remón J and Rosell R: The epidermal
growth factor receptor (EGRF) in lung cancer. Transl Respir Med.
3:12015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Corso G, Velho S, Paredes J, Pedrazzani C,
Martins D, Milanezi F, Pascale V, Vindigni C, Pinheiro H, Leite M,
et al: Oncogenic mutations in gastric cancer with microsatellite
instability. Eur J Cancer. 47:443–451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu
Z, Xue C, Zhang J, Zhang J, Ma Y, et al: Network meta-analysis of
erlotinib, gefitinib, afatinib and icotinib in patients with
advanced non-small-cell lung cancer harboring EGFR mutations. PLoS
One. 9:e852452014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Lin Y, Lan F, Yu Y, Ouyang X, Wang
X, Huang Q, Wang L, Tan J and Zheng F: A GG allele of 30′-side AKT1
SNP is associated with decreased AKT1 activation and better
prognosis of gastric cancer. J Cancer Res Clin Oncol.
140:1399–1411. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu W, Zhong S, Chen J and Yu Y: HER-2/neu
overexpression is an independent prognostic factor for
intestinal-type and early-stage gastric cancer patients. J Clin
Gastroenterol. 46:e31–e37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng HC, Zheng YS, Xia P, Xu XY, Xing YN,
Takahashi H, Guan YF and Takano Y: The pathobiological behaviors
and prognosis associated with Japanese gastric adenocarcinomas of
pure WHO histological subtypes. Histol Histopathol. 25:445–452.
2010.PubMed/NCBI
|
|
15
|
Huang Q, Lan F, Zheng Z, Xie F, Han J,
Dong L, Xie Y and Zheng F: Akt2 kinase suppresses
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-mediated apoptosis
in ovarian cancer cells via phosphorylating GAPDH at threon. J Biol
Chem. 286:42211–42220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nyåkern M, Cappellini A, Mantovani I and
Martelli AM: Synergistic induction of apoptosis in human leukemia T
cells by the Akt inhibitor perifosine and etoposide through
activation of intrinsic and Fas-mediated extrinsic cell death
pathways. Mol Cancer Ther. 5:1559–1570. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Damyanov D, Koynov K, Naseva E and Bichev
S: EGFR mutations in patients with non small-cell lung cancer in
Bulgaria and treatment with gefitinib. J BUON. 20:136–141.
2015.PubMed/NCBI
|
|
18
|
Thiel A and Ristimäki A: Targeted therapy
in gastric cancer. APMIS. 123:365–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee J, Kim KM, Kang WK and Ou SH:
Innovative personalized medicine in gastric cancer: Time to move
forward. Clin Genet. 86:37–43. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS,
Park SR, Han HS, Chung IJ, Song EK, Lee KH, et al: Multicenter
phase II study of trastuzumab in combination with capecitabine and
oxaliplatin for advanced gastric cancer. Eur J Cancer. 51:482–488.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chua C, Tan IB, Yamada Y, Rha SY, Yong WP,
Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, et al: Phase II study of
trastuzumab in combination with S-1 and cisplatin in the first-line
treatment of human epidermal growth factor receptor HER2-positive
advanced gastric cancer. Cancer Chemother Pharmacol. 76:397–408.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jackman DM, Miller VA, Cioffredi LA, Yeap
BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV and Johnson
BE: Impact of epidermal growth factor receptor and KRAS mutations
on clinical outcomes in previously untreated non-small cell lung
cancer patients: Results of an online tumor registry of clinical
trials. Clin Cancer Res. 15:5267–5273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Keller J, Nimnual AS, Varghese MS,
VanHeyst KA, Hayman MJ and Chan EL: A novel EGFR extracellular
domain mutant, EGFRΔ768, possesses distinct biological and
biochemical properties in neuroblastoma. Mol Cancer Res.
14:740–752. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hotta K, Sasaki J, Saeki S, Takigawa N,
Katsui K, Takayama K, Nogami N, Shioyama Y, Bessho A, Kishimoto J,
et al: Gefitinib combined with standard chemoradiotherapy in
EGFR-mutant locally advanced non-small-cell lung cancer: The
LOGIK0902/OLCSG0905 intergroup study protocol. Clin Lung Cancer.
17:75–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK,
Yang D and Zeng YX: EGFR tyrosine kinase inhibitor AG1478 inhibits
cell proliferation and arrests cell cycle in nasopharyngeal
carcinoma cells. Cancer Lett. 169:27–32. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen N, Ma WY, She QB, Wu E, Liu G, Bode
AM and Dong Z: Transactivation of the epidermal growth factor
receptor is involved in
12-O-tetradecanoylphorbol-13-acetate-induced signal transduction. J
Biol Chem. 276:46722–46728. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ke EE and Wu YL: EGFR as a pharmacological
target in EGFR-mutant non-small-cell lung cancer: Where do we stand
now? Trends Pharmacol Sci. 37:887–903. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
D'Anneo A, Carlisi D, Emanuele S, Buttitta
G, Di Fiore R, Vento R, Tesoriere G and Lauricella M: Parthenolide
induces superoxide anion production by stimulating EGF receptor in
MDA-MB-231 breast cancer cells. Int J Oncol. 43:1895–1900.
2013.PubMed/NCBI
|
|
29
|
Arany I, Megyesi JK, Nelkin BD and
Safirstein RL: STAT3 attenuates EGFR-mediated ERK activation and
cell survival during oxidant stress in mouse proximal tubular
cells. Kidney Int. 70:669–674. 2006. View Article : Google Scholar : PubMed/NCBI
|
